FY2027 EPS Estimate for IceCure Medical Lowered by Analyst

IceCure Medical Ltd (NASDAQ:ICCM) – Equities researchers at Brookline Capital Management lowered their FY2027 earnings per share estimates for shares of IceCure Medical in a research report issued on Tuesday, November 26th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.23 for the year, down from their prior estimate of $0.25. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.27) per share. Brookline Capital Management also issued estimates for IceCure Medical’s FY2028 earnings at $0.33 EPS.

Several other brokerages have also weighed in on ICCM. HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a research report on Wednesday. Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM opened at $0.83 on Thursday. IceCure Medical has a one year low of $0.48 and a one year high of $1.57. The company has a current ratio of 2.67, a quick ratio of 2.54 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.72. The firm has a market capitalization of $37.96 million, a price-to-earnings ratio of -2.87 and a beta of 0.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.